Trial · NCT01404650
Results by group29
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 29
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | AUY922 | 3.9 | 95% Confidence Interval 2.5 to 5.3 | months | |
| Response Rate (RR) | AUY922 | Stable Disease | 60 | percentage of participants | |
| Response Rate (RR) | AUY922 | Objective Response | 4 | percentage of participants | |
| Response Rate (RR) | AUY922 | Progressive Disease | 20 | percentage of participants | |
| Overall Survival (OS) | AUY922 | 8.5 | 95% Confidence Interval 5.2 to 16.7 | months | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Anemia | 10 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Leukopenia | 1 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Thrombocytopenia | 1 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Diarrhea | 16 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Fatigue | 13 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Nausea | 11 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Vomiting | 7 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Asthenia | 5 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Abdominal Pain | 3 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Headache | 3 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Pain | 3 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Alkaline phosphatase increased | 2 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Anorexia | 2 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Dehydration | 2 | participants | |
| Number of Patients With Adverse Events as a Measure of Safety and Tolerability | AUY922 | Dysgeusia | 2 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01404650/results